Picture loading failed.

Anti-TNFRSF13C therapeutic antibody (Pre-made Ianalumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ianalumab (INN; development code VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-256-1mg 1mg 3090
GMP-Bios-ab-256-10mg 10mg 21890
GMP-Bios-ab-256-100mg 100mg 148000
GMP-Bios-ab-256-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-TNFRSF13C therapeutic antibody (Pre-made Ianalumab biosimilar,Whole mAb)
INN Name Ianalumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II/III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2017
Year Recommended2018
CompaniesH. Lee Moffitt Cancer Center and Research Institute;MorphoSys;Novartis
Conditions Approvedna
Conditions ActiveAutoimmune hepatitis;Idiopathic pulmonary fibrosis;Multiple sclerosis;Pemphigus vulgaris;Rheumatoid arthritis;Sjogren's syndrome;Systemic lupus erythematosus;Chronic lymphocytic leukaemia
Conditions Discontinuedna
Development TechPOTELLIGENT Technology